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Introduction
Ovarian cancer (OC) is the fifth leading cause of cancer deaths in women, the leading cause of death from gynecological malignancy, and the second most commonly diagnosed gynecological malignancy. According to the data published by National Cancer Institute, there are 21 650 new cases and 15 520 deaths from OC in the United States in 2008. Unfortunately, at the present time there is no effective treatment for OC because the mechanism(s) by which OC develops remains largely unknown. It is therefore that understanding the mechanism for the progression of OC will greatly help to develop more effective treatments for patients with OC.
Extracellular Ca 2 þ entry and subsequent elevation of intracellular Ca 2 þ concentration ([Ca 2 þ ] i ) play a critical role in the cell-cycle progression (Dolmetsch et al., 1998; Kahl and Means, 2003) and Ca 2 þ -mediated signaling is involved in many cancer traits (Monteith et al., 2007; Roderick and Cook, 2008) . The transient receptor potential (TRP) channels are nonselective cation channels permeant to Ca 2 þ (Clapham et al., 2001) . The TRP superfamily can be divided into seven subfamilies: TRPC, TRPV, TRPM, TRPN, TRPA, TRPP and TRPML (Venkatachalam and Montell, 2007) . These channels have critical roles in physiological processes ranging from sensation to fertilization (Venkatachalam and Montell, 2007) . Mammalian TRPCs fall into four groups based on the amino-acid similarity: TRPC1, TRPC2 (pseudogene in human), TRPC3/6/7 and TRPC4/5. Recently, upregulation of TRPC6 has been shown to contribute to pulmonary artery smooth muscle cell proliferation (Yu et al., 2003) and to pulmonary vascular medial hypertrophy of idiopathic pulmonary arterial hypertension patients (Yu et al., 2004) . TRPC6 promotes the proliferation of prostate cancer epithelial cells (Thebault et al., 2006) and human hepatoma cells (El Boustany et al., 2008) .
As TRPC3 shares about 75% homology with TRPC6 and TRPC3 could compensate the function of TRPC6 in trpc6À/À mice (Dietrich et al., 2005) , we asked whether TRPC3 also plays a role in cell proliferation. In this study, we provide evidence that TRPC3 protein levels were markedly increased in human OC specimens than those in normal ovarian specimens. Decreased the expression of TRPC3 reduced the proliferation of cultured human OC cells, arrested the cell cycle at M phase and restrained the growth of SKOV3 cells in nude mice. Our results thus suggest that TRPC3 channels play a critical role in the development of human OC.
Results

Increased expression of TRPC3 in human epithelial ovarian cancer
To explore the possible role of TRPC3 in the development of human epithelial OC, we first examined the expression level of these channel proteins in human specimens. We determined the specificity of an antibody against TRPC3 using the lysates isolated from the HEK293 cells transfected with Myc-tagged human wild-type TRPC3 or an empty plasmid as a control. As shown in Figure 1a , the antibody recognized both endogenous and the overexpressed TRPC3. Similarly, anti-Myc antibody detected the bands at the same migration positions as those detected by the anti-TRPC3 antibody. The predicted molecular mass of the overexpressed TRPC3 is 93.5 kD and the antibody recognized a band around 100 kD. The difference in the molecular weight is likely due to its posttranslational modification because the glycosylation of TRPC3 has been reported . Then we also verified the specificity of the antibody in recognizing endogenous TRPC3 in the SKOV3 cell lysates, a human OC cell line well used in study of OC development. As shown in Figure 1b , the antibody recognized one predominant band around 100 kD, a molecular weight which is consistent with that reported in previous publications and with that of the overexpressed TRPC3 in HEK239 cells. Moreover, this band can be blocked by the antigenic peptide. These results indicate that the anti-TRPC3 antibody really recognizes TRPC3 proteins. We then used the antibody to investigate the protein level of TRPC3 in 28 ovarian epithelial tumor samples and 22 normal ovaries by western blot (Figure 1c ). As shown in Figure 1b , the expression level of TRPC3 in 29% (8 of 28) of ovarian surface epithelial tumor samples are 4.3-fold higher than that in normal ovary samples, 42% (12 of 28) of the tumor samples are about 1.6-fold higher than that in normal ones and 29% (8 of 28) of tumor samples are almost the same as that in normal specimens. Together, these results provide us initial evidence that TRPC3 channels may play a role in the development of human epithelial OC.
Knocking-down TRPC3 suppressed OC cell growth To study whether TRPC3 channels are possibly involved in OC development, we examined the effect of inhibition of TRPCs on OC cell growth with SKF96365 at SKOV3 cells in which the TRPC3 mRNA is highly expressed (Supplementary Figure 1a) . The growth ability of SKOV3 cells was markedly reduced by SKF96365 and the growth inhibition of SKF96365 was dose dependent (Supplementary Figure 1b) . To avoid potential nonspecific effects of SKF96365, we introduced chemically synthesized siRNAs against two domains of TRPC3 mRNA into the SKOV3 cells. Western blot analysis showed that 72 h after transfection the protein level of TRPC3 in the siRNAs-transfected cells was reduced compared with that in control siRNA-transfected cells (Figure 2a and Supplementary  Figure 2) . The cell numbers were also reduced when TRPC3 was knocked down. It is known that heterogeneity is common to tumors. We thus examined whether inhibition of TRPC3 also affects growth of two additional human OC cell lines, ES2 and CAOV3 in which TRPC3 is expressed ( Supplementary Figure 3a and b). As shown in Figure 2a , knocking-down TRPC3 also reduce cell growth ability in these two cell lines. These results indicate that TRPC3 contributes the growth of OC cells with heterogeneity. We then used SKOV3 cells as the model cells.
The finding that diminished expression of TRPC3 reduced the growth of SKOV3 cells was also found in the SKOV3 cells stably transfected with shRNA against the TRPC3 domain different from those the siRNAs against. The specificity of the shRNA construct against TRPC3 was confirmed in SKOV3 cells stably transfected with the construct. Real-time PCR and western blot showed that TRPC3 at both mRNA and protein levels was greatly reduced, whereas TRPC6 at mRNA and protein levels was not affected in shC3i cells ( Figure 2b ). As shown in Figure 2c , the growth ability was reduced about 28% in shC3i cells the fifth day after seeding. These results using RNAi against three domains of TRPC3 mRNA in transient and stable transfections, all showed that downregulation of TRPC3 suppressed OC cell growth, indicate the specific effect of the RNAi used in the experiments. To study whether TRPC3 affected the cell growth due to its effect on proliferation or on survival, we performed the BrdU incorporation assay. The shN and shC3i cells were labeled with 10 mg/ml BrdU for 3 h, the BrdU-positive cells were 40.43±2.52% in shN cells, whereas it was 30.85 ± 3.37% in shC3i cells. When the cells were labeled for 20 h, the BrdU-positive cells in shN was 83.49±2.95%, whereas it was 65.10±1.94% in shC3i. Together, these results suggest that downregulation of TRPC3 suppressed the proliferation of SKOV3 cells leading to inhibition of their growth. This notion was Downregulating TRPC3 arrested OC cells at M phase To elucidate the mechanism by which inhibition of TRPC3 suppresses OC cell proliferation, we studied the effect of inhibition of TRPC3 on cell cycle. We initially introduced the two siRNAs against TRPC3 (C3i-1 and -2) into the OC cells and examined cell-cycle profile 3 days after transfection. As shown in Figure 3a , the percentage of cells found in G 2 /M phase was substantially increased with a concomitant reduction in the percentage of cells in G 0 /G 1 phase, consistent with the observation that SKF96365 treatment arrested the cells in G 2 /M phase (Supplementary Figure 1c) . These results suggest that downregulating TRPC3 induces G 2 /M phase arrest in these cells. We then further analysed the cell-cycle progression in shC3i cells. We first synchronized cells at the G 1 /S boundary by double thymidine arrest and then labeled the cells with BrdU for 2 h after release from thymidine blockade and harvested the cells at different time points to analyse the cell cycle. The shN and shC3i cells showed a marginal difference in progression through the S phase (Figures 3b and c) and they reached the G 2 /M phase at the same time (Figures 3b and c) . But knocking-down TRPC3 prolonged the transition through G 2 /M phase because the decline in percentage of the cells in G 2 /M from shN was quicker than that in shC3i cells and shN cells entered the G 1 phase faster (Figure 3c ). These results suggest that knocking-down TRPC3 inhibited the progression through G 2 /M to G 1 . Western blot analysis further showed that when TRPC3 was downregulated, the level of phosphorylated form of Cdc2 (Tyr 15) was markedly reduced without affecting the total level of Cdc2, and the level of Cyclin B1 was increased (Figure 3d ). Moreover, staining the cells with MPM2 mitotic phosphoepitope antibody and 
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Hochest showed that the percentage of mitotic cells was 4.28 ± 0.27 or 7.6 ± 0.13% in shN or shC3i, respectively (Figure 3d ). Together, these results suggest that the OC cells were arrested at M phase when TRPC3 was downregulated.
Functional TRPC3 was present in OC cells and contributed to their metaphase exit TRPC3 channels are nonselective cation channels permeant to Na þ and Ca 2 þ (Hurst et al., 1998; Lintschinger et al., 2000; Zitt et al., 1997) . The TRPC3 may affect [Ca 2 þ ] i change through two reported pathways, including Ca 2 þ influx directly through TRPC3 channels (Zhu et al., 1996; Zitt et al., 1997) (Auersperg et al., 1998; Maihle et al., 2002; Nicosia et al., 2003; Psyrri et al., 2005) . It has been reported that EGF can activate TRPC3, 4 and 5, to induce Ca 2 þ influx in HEK293 cells (Bezzerides et al., 2004; Odell et al., 2005; Smyth et al., 2006; Yang et al., 2005) . As shown in Figure 4a, (Figures 4d  and e) . Together, these results suggest that OC cells did express functional TRPC3 channels.
It has been reported that Ca 2 þ is necessary for metaphase to anaphase transition through regulation of CaMKIIa (Hansen et al., 2006; Liu and Maller, 2005; Lorca et al., 1993; Rauh et al., 2005) . We then examined the effect of inhibition of TRPC3 on activation of CaMKIIa. As shown in Figure 4f , the phosphorylation of CaMKIIa at Thr 286, a site known to be critical for its activation (Fong et al., 1989) , was substantially inhibited when TRPC3 was downregulated. Therefore, these results are consistent with an explanation that knocking-down TRPC3 inhibited CaMKIIa to prolong the duration of the M phase. To further test this idea, we synchronized the cells with nocodazole and collected the cells at different time points after removal of nocodazole. As shown in Figure 4g , treatment with nocodazole caused about 25% of both shN and shC3i cells in M phase (24.84 ± 2.08 vs 24.95 ± 2.49, P ¼ 0.4680). Four hours after removing nocodazole, 16.64±2.34% of shC3i cells was in M phase, whereas 9.39±1.81% of the shN cells was in M phase (Po0.01). Moreover, 6 h after release from M phase, the mitotic index of control cells was similar to the one in background (6.09 ± 1.25%), whereas 13.21 ± 2.09% of shC3i cells remained in M phase. These results suggest that suppressing TRPC3 decelerated the metaphase exit in SKOV3 cells through inactivating CaMKIIa.
Downregulating TRPC3 suppressed development of tumor in nude mice
To provide direct evidence that TRPC3 indeed plays an important role in OC development, we subcutaneously injected the SKOV3 cells transfected with siRNAs to the nude mice. We killed the nude mice and measured the weights of the tumor formed by transfected OC cells 3 weeks later and found that the size of tumors formed by the SKOV3 cells transfected with siRNAs targeting TRPC3 was much smaller than that formed by the cells transfected with nonsense siRNA (Figure 5a ). We then further confirmed these findings using the shRNA with a different sequence. We subcutaneously injected shN and shC3i cells into the nude mice to detect the tumorigenic abilities of these cells. As shown in Figure 5b , the tumor volumes determined at different times after the injection in shN group were greater than those in shC3i group, indicating that suppressing TRPC3 inhibited the tumor growth. Moreover, at day 40, all nude mice were killed and the tumors were taken out. The average weight of the tumor generated from shN was 0.285±0.085 g, whereas the average weight of the tumor generated from shC3i was 0.174 ± 0.055 g. These results suggest that TRPC3 channels are really responsible for ovarian tumor development in vivo. 
Discussion
In this work, we have shown that TRPC3 channels play a critical role in OC development. Several lines of evidence support this conclusion. First, expression of TRPC3 was greatly enhanced in human OC. Second, OC cells did express functional TRPC3 channels and blockade of TRPC3 inhibited [Ca 2 þ ] i elevation stimulated by EGF. Third, inhibition of TRPC3 dephosphorylated Cdc2 at Tyr15 and arrested OC cells at M phase. Finally, inhibition of TRPC3 suppressed OC cell growth in culture and in nude mice. Our results thus suggest that [Ca 2 þ ] i regulated by TRPC3 channels is important for OC development.
It has been reported that Ca 2 þ might be involved in tumorigenesis through multiple mechanisms including regulating Ras activity (Cook and Lockyer, 2006; Cullen and Lockyer, 2002) , inducing PTEN nuclear translocation (Minaguchi et al., 2006) and modulating cell cycle. The increase in expression of Ca 2 þ channel proteins could enhance the Ca 2 þ influx and promote cell proliferation (Berridge et al., 2003) . The Ca 2 þ influx also affect OC cell proliferation (Popper and Batra, 1993; Schultze-Mosgau et al., 2000) . Carboxyamidotriazole, a cytostatic inhibitor of non-voltage-operated Ca 2 þ channels, has been tested as a potential therapeutic drug to patients with OC in phase I and II clinical trails (Hussain et al., 2003; Kohn et al., 1996) . But the Ca 2 þ channels responsible for OC development have not been known. Our results here thus suggest that TRPC3 channels might be novel targets for therapeutic intervention of OC.
One important finding of the current report is that [Ca 2 þ ] i affected by TRPC3 is important for OC cellcycle progression. Indeed, changes in [Ca 2 þ ] i actively modulate M phase progression in oocytes and in mammalian fibroblasts and epithelial cells (Kao et al., 1990; Tombes and Borisy, 1989; Xu et al., 2003) . The Ca 2 þ -dependent anaphase onset is accompanied by a sustained elevation of [Ca 2 þ ] i (Tombes and Borisy, 1989) . We showed here that the sustained elevation of [Ca 2 þ ] i and the activity of CaMKIIa in OC cells were inhibited by downregulating TRPC3. As CaMKIIa ensures the M phase exit from metaphase (Hansen et al., 2006; Liu and Maller, 2005; Lorca et al., 1993) , it is possible that in OC cells, [Ca 2 þ ] i elevation regulated by TRPC3 subsequently activates CaMKIIa to promote the exit of cells from metaphase and increase the OC cell proliferation. Alternatively, the calcineurin/NFAT signaling, a pathway known important for cell proliferation and activated by TRPC6 (Thebault et al., 2006) or TRPC3 (Rosenberg et al., 2004; Thebault et al., 2005) , might be involved in OC cell-cycle regulation by TRPC3. Indeed, calcineurin has recently been found to work with CaMKIIa to release Xenopus egg extract from meiotic M phase (Mochida and Hunt, 2007) .
Calcium ion is a ubiquitous signal involved in every aspect of cellular process from growth to death. Thus the [Ca 2 þ ] i must be regulated to precisely respond to the stimulus. Many cancer cells need to change the expression or activation of their Ca 2 þ signaling apparatus to maintain proliferation and avoid apoptosis. In OC, we found that TRPC3 channels promote the cell proliferation and inhibition of these channels leads to suppression of OC cell growth. It is thus possible that TRPC3 might be a novel target for therapeutic intervention to treatment of human ovarian epithelial cancers.
Materials and methods
Materials
Antibodies against Cyclin B1, Cdc2, phospho-Cdc2 (Tyr 15), anti-Myc tag antibody and secondary antibodies were from Cell Signaling (Danvers, MA, USA), anti-TRPC6 antibody from Santa Cruz (Santa Cruz, CA, USA), anti-TRPC3 antibody from Alomone Labs (Jerusalem, Israel), antibody for MPM2 from Abcam (Cambridge, MA, USA), Alexa Fluor 488-goat anti-rabbit immunoglobulin g (IgG) and Texas Red-X goat anti-mouse IgG from Molecular Probes (Eugene, OR, USA), FITC-conjugated anti-BrdUrd antibody from BD (San Jose, CA, USA). Clinical specimens were collected from the patients registered at The Obstetrics and Gynecology Hospital of Medical Center, Fudan University (Shanghai, China) with patients' consent and ethical committee approval. All other reagents were from Sigma (St Louis, MO, USA).
Cell culture and constructs
The SKOV-3 cells were maintained in McCoy's 5a supplemented with 10% (v/v) fetal calf serum (Invitrogen, Carlsbad, CA, USA) and incubated at 37 1C with 5% CO 2 . For determination of growth curve, cells were seeded in six-well plates at 3 Â 10
5
. The attached cells were trypsinized and the cell numbers were then determined by counting with a Z1 Coulter counter (Beckman Coulter, Fullerton, CA, USA) every 24 h. All experiments were performed in triplicate and medium was replaced every 48 h. The Myc-tagged human wildtype TRPC3 was generated by PCR using pCAGGS-hTRPC3 (Jia et al., 2007) and inserted into pcDNA3.1. We generated shC3i, short hairpin RNAi constructs targeting TRPC3, and shN as a control. The SKOV-3 cells stably transfected with shC3i or shN were generated as previously described (Brummelkamp et al., 2002) . The sense sequence of shC3i was 5 0 -AAGGCATGGGTATATGGAAAT-3 0 , and the control sequence of shN was 5 0 -AACGTGACACGTTCGGA GAAT-3 0 . Transfection was performed by electroporation using the Nucleofector Device (Amaxa, Cologne, Germany).
Western blotting
Patient samples and cells were sonicated and centrifuged to pellet cell debris. Proteins were separated on SDS-PAGE, transferred to PVDF membranes (Amersham, Buckinghamshire, UK) and probed with primary antibodies and secondary antibodies conjugated with horseradish peroxidase. The protein bands were visualized by the Amersham ECL system and scanned. Their densities were determined by ImageQuant 5.2 software (Amersham).
Real-time PCR
Total RNA isolated from cells using Trizol Reagent (Invitrogen) was reverse transcribed into cDNA. The mRNA levels of TRPC3, TRPC6 and GAPDH were then determined by realtime PCR. The primers used were synthesized according to the previous report (Zagranichnaya et al., 2005) . Real-time PCR was carried out using SYBR green PCR master mix (TaKaRa, Otus, Shiga, Japan). Amplification and detection were performed using ABI Prism 7700 system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions.
Intracellular Ca
2 þ image Cells were cultured on glass coverslips and loaded with 2 mM fura-2-acetoxymethyl ester in McCoy'5a at 37 1C for 30 min, then incubated in HBSS buffer (120 mmol/l NaCl, 6 mmol/l KCl, 2 mmol/l CaCl 2 , 2mmol/l MgCl 2 , 12 mmol/l glucose and 10 mmol/l HEPES, pH 7.4) for 10 min at room temperature before used. For Ca 2 þ -free HBSS buffer, CaCl 2 was removed and 0.5 mmol/l EGTA was added. Fluorescence was recorded by Nikon eclipse Te2000 microscope excited at 340 and 380 nm wavelengths every 3 s and emission was measured at 510 nm. Changes in [Ca2 þ ] i were monitored as 340/380 fluorescence ratio.
RNA interference
The sequences of siRNA duplexes targeting TRPC3 were hTRPC3i.1:
0 -UUC AAC ACA AUG GUA UGC Cdtdt-3 0 (antisense). The siRNA for negative control was 5 0 -UUCUCCGAAC GUGUCACGUdtdt-3 0 (sense), 5 0 -ACGUGACACGUUCG GAGAAdtdt-3 0 (antisense). Transfection of the cells with siRNA was conducted by eletroporation using the Nucleofector Device (Amaxa).
BrdUrd incorporation
Cells were cultured on the glass coverslips, incubated with the medium containing 10 mM BrdUrd for the indicated times and fixed with 4% paraformaldehyde. Then the fixed cells were treated with 2 N HCl for 30 min and 0.1 M Na 2 B 4 O 7 for another 30 min at 37 1C. Following steps were done as immunostaining.
Focus formation
A total of 500 cells from the two cell lines stably transfected with shN or shC3i were seeded in 35 mm dishes separately in triplicate. The culture medium contained 600 mg/l G418 to maintain the shRNAi expression. Three weeks later, the colonies were fixed with 4% paraformaldehyde, permeated with 20% methanol and stained with crystal violet. Total colony number and the large colony (d>1 mm) number were counted under microscope.
Cell-cycle analysis Cells were synchronized in G 1 /S with a double thymidine treatment. Cells were plated at 5 Â 10 5 in 60-mm dish for 24 h. The medium was changed into the fresh medium containing 4 mm thymidine for 20 h. Then the cells were washed twice with phosphate-buffered saline (PBS) and incubated with fresh medium for 12 h. Cells were then reincubated with the medium containing 4 mm thymidine for another 16 h. Then the cells were released from thymidine block and labeled with BrdU for 2 h. At the indicated times the cells were harvested by trypsinization and stained with FITC-conjugated anti-BrdUrd IgG and 7AAD. The flow cytometer analysis was performed to determine the number of BrdU-positive cells at each stage of the cell cycle. To induce the mitotic spindle checkpoint, nocodazole was added 5 h after release from G 1 /S block to a final concentration of 0.4 mg/ml for 12 h. At the indicated times after release, cells were fixed and stained sequentially with anti-MPM2 antibody, Texas Red-X goat anti-mouse IgG and Hochest. The MPM2 and Hochest-positive cells were counted manually using fluorescence microscope.
Immunostaining
The cells grown on chamber slides were fixed with 4% paraformaldehyde, washed with PBS, and then incubated for 30 min with 5% normal goat serum in PBS. They were then exposed to primary antibodies and Alexa Fluor 488-goat antirabbit or Texas Red-X goat anti-mouse secondary antibodies. Slides were mounted in medium containing Hoechst 33258 and imaged with a fluorescent microscope. 
Statistical analysis
Multiple comparisons were assessed by one-way analysis of variance in nonparametric statistics; otherwise Student's unpaired t-test was used for statistical analysis. Results were considered significant difference at *Po0.05; **Po0.01.
